nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP3A4—Thiotepa—sarcoma	0.122	0.169	CbGbCtD
Levomilnacipran—ABCB1—Dactinomycin—sarcoma	0.0978	0.136	CbGbCtD
Levomilnacipran—ABCB1—Mitoxantrone—sarcoma	0.0875	0.121	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—sarcoma	0.0815	0.113	CbGbCtD
Levomilnacipran—ABCB1—Vincristine—sarcoma	0.0602	0.0835	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—sarcoma	0.0552	0.0765	CbGbCtD
Levomilnacipran—CYP3A4—Mitoxantrone—sarcoma	0.0524	0.0727	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—sarcoma	0.0376	0.0522	CbGbCtD
Levomilnacipran—CYP3A4—Vincristine—sarcoma	0.0361	0.05	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—sarcoma	0.0355	0.0492	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—sarcoma	0.0331	0.0458	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—sarcoma	0.0226	0.0313	CbGbCtD
Levomilnacipran—Hot flush—Doxorubicin—sarcoma	0.000737	0.00264	CcSEcCtD
Levomilnacipran—Hypotension—Mitoxantrone—sarcoma	0.000733	0.00263	CcSEcCtD
Levomilnacipran—Migraine—Epirubicin—sarcoma	0.000733	0.00263	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Doxorubicin—sarcoma	0.00073	0.00262	CcSEcCtD
Levomilnacipran—Insomnia—Vincristine—sarcoma	0.000729	0.00262	CcSEcCtD
Levomilnacipran—Paraesthesia—Vincristine—sarcoma	0.000724	0.0026	CcSEcCtD
Levomilnacipran—Urticaria—Thiotepa—sarcoma	0.000722	0.00259	CcSEcCtD
Levomilnacipran—Abdominal pain—Thiotepa—sarcoma	0.000719	0.00258	CcSEcCtD
Levomilnacipran—Body temperature increased—Thiotepa—sarcoma	0.000719	0.00258	CcSEcCtD
Levomilnacipran—Leukopenia—Etoposide—sarcoma	0.000716	0.00257	CcSEcCtD
Levomilnacipran—Abdominal pain—Dactinomycin—sarcoma	0.000713	0.00256	CcSEcCtD
Levomilnacipran—Body temperature increased—Dactinomycin—sarcoma	0.000713	0.00256	CcSEcCtD
Levomilnacipran—Paraesthesia—Mitoxantrone—sarcoma	0.000705	0.00253	CcSEcCtD
Levomilnacipran—Loss of consciousness—Etoposide—sarcoma	0.000703	0.00252	CcSEcCtD
Levomilnacipran—Decreased appetite—Vincristine—sarcoma	0.000701	0.00251	CcSEcCtD
Levomilnacipran—Dyspnoea—Mitoxantrone—sarcoma	0.0007	0.00251	CcSEcCtD
Levomilnacipran—Somnolence—Mitoxantrone—sarcoma	0.000698	0.0025	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Vincristine—sarcoma	0.000696	0.0025	CcSEcCtD
Levomilnacipran—Fatigue—Vincristine—sarcoma	0.000695	0.00249	CcSEcCtD
Levomilnacipran—Convulsion—Etoposide—sarcoma	0.000693	0.00249	CcSEcCtD
Levomilnacipran—Hyponatraemia—Doxorubicin—sarcoma	0.000692	0.00248	CcSEcCtD
Levomilnacipran—Dyspepsia—Mitoxantrone—sarcoma	0.000691	0.00248	CcSEcCtD
Levomilnacipran—Hypertension—Etoposide—sarcoma	0.000691	0.00248	CcSEcCtD
Levomilnacipran—Constipation—Vincristine—sarcoma	0.000689	0.00247	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Epirubicin—sarcoma	0.000687	0.00247	CcSEcCtD
Levomilnacipran—Dry skin—Epirubicin—sarcoma	0.000683	0.00245	CcSEcCtD
Levomilnacipran—Decreased appetite—Mitoxantrone—sarcoma	0.000682	0.00245	CcSEcCtD
Levomilnacipran—Chest pain—Etoposide—sarcoma	0.000681	0.00244	CcSEcCtD
Levomilnacipran—Migraine—Doxorubicin—sarcoma	0.000678	0.00243	CcSEcCtD
Levomilnacipran—Fatigue—Mitoxantrone—sarcoma	0.000677	0.00243	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000676	0.00243	CcSEcCtD
Levomilnacipran—Breast disorder—Epirubicin—sarcoma	0.000673	0.00241	CcSEcCtD
Levomilnacipran—Constipation—Mitoxantrone—sarcoma	0.000671	0.00241	CcSEcCtD
Levomilnacipran—Hypersensitivity—Thiotepa—sarcoma	0.00067	0.0024	CcSEcCtD
Levomilnacipran—Hypersensitivity—Dactinomycin—sarcoma	0.000665	0.00239	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Vincristine—sarcoma	0.000659	0.00237	CcSEcCtD
Levomilnacipran—Asthenia—Thiotepa—sarcoma	0.000652	0.00234	CcSEcCtD
Levomilnacipran—Infection—Etoposide—sarcoma	0.000649	0.00233	CcSEcCtD
Levomilnacipran—Abdominal distension—Epirubicin—sarcoma	0.000648	0.00232	CcSEcCtD
Levomilnacipran—Asthenia—Dactinomycin—sarcoma	0.000647	0.00232	CcSEcCtD
Levomilnacipran—Pruritus—Thiotepa—sarcoma	0.000643	0.00231	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000642	0.0023	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Etoposide—sarcoma	0.000639	0.00229	CcSEcCtD
Levomilnacipran—Tachycardia—Etoposide—sarcoma	0.000637	0.00229	CcSEcCtD
Levomilnacipran—Abdominal pain—Vincristine—sarcoma	0.000637	0.00229	CcSEcCtD
Levomilnacipran—Body temperature increased—Vincristine—sarcoma	0.000637	0.00229	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Doxorubicin—sarcoma	0.000636	0.00228	CcSEcCtD
Levomilnacipran—Skin disorder—Etoposide—sarcoma	0.000634	0.00228	CcSEcCtD
Levomilnacipran—Dry skin—Doxorubicin—sarcoma	0.000632	0.00227	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Etoposide—sarcoma	0.000631	0.00226	CcSEcCtD
Levomilnacipran—Angina pectoris—Epirubicin—sarcoma	0.000627	0.00225	CcSEcCtD
Levomilnacipran—Urticaria—Mitoxantrone—sarcoma	0.000624	0.00224	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—sarcoma	0.000623	0.00223	CcSEcCtD
Levomilnacipran—Anorexia—Etoposide—sarcoma	0.000622	0.00223	CcSEcCtD
Levomilnacipran—Diarrhoea—Thiotepa—sarcoma	0.000622	0.00223	CcSEcCtD
Levomilnacipran—Abdominal pain—Mitoxantrone—sarcoma	0.00062	0.00223	CcSEcCtD
Levomilnacipran—Body temperature increased—Mitoxantrone—sarcoma	0.00062	0.00223	CcSEcCtD
Levomilnacipran—Diarrhoea—Dactinomycin—sarcoma	0.000617	0.00221	CcSEcCtD
Levomilnacipran—Hypotension—Etoposide—sarcoma	0.00061	0.00219	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—sarcoma	0.000602	0.00216	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—sarcoma	0.000602	0.00216	CcSEcCtD
Levomilnacipran—Dizziness—Thiotepa—sarcoma	0.000601	0.00216	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—sarcoma	0.000599	0.00215	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—sarcoma	0.000598	0.00215	CcSEcCtD
Levomilnacipran—Pollakiuria—Epirubicin—sarcoma	0.000595	0.00213	CcSEcCtD
Levomilnacipran—Hypersensitivity—Vincristine—sarcoma	0.000594	0.00213	CcSEcCtD
Levomilnacipran—Paraesthesia—Etoposide—sarcoma	0.000586	0.0021	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—sarcoma	0.000582	0.00209	CcSEcCtD
Levomilnacipran—Dyspnoea—Etoposide—sarcoma	0.000582	0.00209	CcSEcCtD
Levomilnacipran—Somnolence—Etoposide—sarcoma	0.00058	0.00208	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—sarcoma	0.00058	0.00208	CcSEcCtD
Levomilnacipran—Hypersensitivity—Mitoxantrone—sarcoma	0.000578	0.00208	CcSEcCtD
Levomilnacipran—Asthenia—Vincristine—sarcoma	0.000578	0.00208	CcSEcCtD
Levomilnacipran—Vomiting—Thiotepa—sarcoma	0.000578	0.00207	CcSEcCtD
Levomilnacipran—Vomiting—Dactinomycin—sarcoma	0.000574	0.00206	CcSEcCtD
Levomilnacipran—Rash—Thiotepa—sarcoma	0.000573	0.00206	CcSEcCtD
Levomilnacipran—Dermatitis—Thiotepa—sarcoma	0.000573	0.00205	CcSEcCtD
Levomilnacipran—Headache—Thiotepa—sarcoma	0.000569	0.00204	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000569	0.00204	CcSEcCtD
Levomilnacipran—Rash—Dactinomycin—sarcoma	0.000569	0.00204	CcSEcCtD
Levomilnacipran—Decreased appetite—Etoposide—sarcoma	0.000568	0.00204	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Etoposide—sarcoma	0.000564	0.00202	CcSEcCtD
Levomilnacipran—Asthenia—Mitoxantrone—sarcoma	0.000563	0.00202	CcSEcCtD
Levomilnacipran—Fatigue—Etoposide—sarcoma	0.000563	0.00202	CcSEcCtD
Levomilnacipran—Constipation—Etoposide—sarcoma	0.000558	0.002	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—sarcoma	0.000558	0.002	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—sarcoma	0.000557	0.002	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—sarcoma	0.000557	0.002	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000553	0.00199	CcSEcCtD
Levomilnacipran—Diarrhoea—Vincristine—sarcoma	0.000551	0.00198	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—sarcoma	0.00055	0.00197	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—sarcoma	0.000547	0.00196	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Epirubicin—sarcoma	0.000543	0.00195	CcSEcCtD
Levomilnacipran—Nausea—Thiotepa—sarcoma	0.00054	0.00194	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—sarcoma	0.000539	0.00193	CcSEcCtD
Levomilnacipran—Diarrhoea—Mitoxantrone—sarcoma	0.000537	0.00193	CcSEcCtD
Levomilnacipran—Nausea—Dactinomycin—sarcoma	0.000536	0.00192	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Etoposide—sarcoma	0.000534	0.00192	CcSEcCtD
Levomilnacipran—Dizziness—Vincristine—sarcoma	0.000533	0.00191	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000526	0.00189	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—sarcoma	0.000519	0.00186	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—sarcoma	0.000516	0.00185	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—sarcoma	0.000516	0.00185	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—sarcoma	0.000516	0.00185	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—sarcoma	0.000515	0.00185	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—sarcoma	0.000513	0.00184	CcSEcCtD
Levomilnacipran—Vomiting—Vincristine—sarcoma	0.000512	0.00184	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—sarcoma	0.000509	0.00183	CcSEcCtD
Levomilnacipran—Rash—Vincristine—sarcoma	0.000508	0.00182	CcSEcCtD
Levomilnacipran—Dermatitis—Vincristine—sarcoma	0.000508	0.00182	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—sarcoma	0.000507	0.00182	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—sarcoma	0.000506	0.00182	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—sarcoma	0.000506	0.00182	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—sarcoma	0.000505	0.00181	CcSEcCtD
Levomilnacipran—Headache—Vincristine—sarcoma	0.000505	0.00181	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—sarcoma	0.000502	0.0018	CcSEcCtD
Levomilnacipran—Vomiting—Mitoxantrone—sarcoma	0.000499	0.00179	CcSEcCtD
Levomilnacipran—Rash—Mitoxantrone—sarcoma	0.000495	0.00178	CcSEcCtD
Levomilnacipran—Dermatitis—Mitoxantrone—sarcoma	0.000494	0.00177	CcSEcCtD
Levomilnacipran—Headache—Mitoxantrone—sarcoma	0.000492	0.00176	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—sarcoma	0.000487	0.00175	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—sarcoma	0.000481	0.00173	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—sarcoma	0.000481	0.00173	CcSEcCtD
Levomilnacipran—Nausea—Vincristine—sarcoma	0.000479	0.00172	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—sarcoma	0.000478	0.00172	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—sarcoma	0.000478	0.00172	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—sarcoma	0.000477	0.00171	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—sarcoma	0.000474	0.0017	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—sarcoma	0.000471	0.00169	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—sarcoma	0.00047	0.00168	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—sarcoma	0.000468	0.00168	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—sarcoma	0.000468	0.00168	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—sarcoma	0.000467	0.00168	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—sarcoma	0.000467	0.00168	CcSEcCtD
Levomilnacipran—Nausea—Mitoxantrone—sarcoma	0.000466	0.00167	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—sarcoma	0.000464	0.00167	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—sarcoma	0.000462	0.00166	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—sarcoma	0.000462	0.00166	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—sarcoma	0.000451	0.00162	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—sarcoma	0.000451	0.00162	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—sarcoma	0.000448	0.00161	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—sarcoma	0.000447	0.0016	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—sarcoma	0.000445	0.0016	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—sarcoma	0.000442	0.00159	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—sarcoma	0.000442	0.00159	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—sarcoma	0.000442	0.00159	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—sarcoma	0.00044	0.00158	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—sarcoma	0.000439	0.00158	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—sarcoma	0.000432	0.00155	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—sarcoma	0.000432	0.00155	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—sarcoma	0.00043	0.00154	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—sarcoma	0.000428	0.00153	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—sarcoma	0.000423	0.00152	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—sarcoma	0.000418	0.0015	CcSEcCtD
Levomilnacipran—Vomiting—Etoposide—sarcoma	0.000415	0.00149	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—sarcoma	0.000415	0.00149	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—sarcoma	0.000412	0.00148	CcSEcCtD
Levomilnacipran—Rash—Etoposide—sarcoma	0.000412	0.00148	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—sarcoma	0.000411	0.00148	CcSEcCtD
Levomilnacipran—Headache—Etoposide—sarcoma	0.000409	0.00147	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—sarcoma	0.000409	0.00147	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—sarcoma	0.000407	0.00146	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—sarcoma	0.000406	0.00146	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—sarcoma	0.000402	0.00144	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—sarcoma	0.000401	0.00144	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—sarcoma	0.000396	0.00142	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—sarcoma	0.000394	0.00141	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—sarcoma	0.000391	0.0014	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—sarcoma	0.000389	0.00139	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—sarcoma	0.000388	0.00139	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—sarcoma	0.000387	0.00139	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—sarcoma	0.000382	0.00137	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—sarcoma	0.000381	0.00137	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—sarcoma	0.00038	0.00137	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000379	0.00136	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—sarcoma	0.000373	0.00134	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—sarcoma	0.000372	0.00134	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—sarcoma	0.000371	0.00133	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—sarcoma	0.000367	0.00132	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—sarcoma	0.000365	0.00131	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—sarcoma	0.000364	0.0013	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—sarcoma	0.00036	0.00129	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—sarcoma	0.000359	0.00129	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—sarcoma	0.000359	0.00129	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—sarcoma	0.000358	0.00129	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—sarcoma	0.000358	0.00129	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—sarcoma	0.000357	0.00128	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—sarcoma	0.000355	0.00128	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—sarcoma	0.000354	0.00127	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—sarcoma	0.000353	0.00127	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—sarcoma	0.000352	0.00126	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000351	0.00126	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—sarcoma	0.000349	0.00125	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—sarcoma	0.000345	0.00124	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—sarcoma	0.000342	0.00123	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—sarcoma	0.000336	0.00121	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—sarcoma	0.000333	0.0012	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—sarcoma	0.000332	0.00119	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—sarcoma	0.000332	0.00119	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—sarcoma	0.000331	0.00119	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—sarcoma	0.00033	0.00119	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—sarcoma	0.000329	0.00118	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—sarcoma	0.000329	0.00118	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—sarcoma	0.000327	0.00117	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—sarcoma	0.000326	0.00117	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—sarcoma	0.000325	0.00117	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—sarcoma	0.000323	0.00116	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—sarcoma	0.000322	0.00116	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—sarcoma	0.000318	0.00114	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—sarcoma	0.000316	0.00114	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—sarcoma	0.000316	0.00113	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—sarcoma	0.000316	0.00113	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—sarcoma	0.000313	0.00112	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—sarcoma	0.000306	0.0011	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—sarcoma	0.000304	0.00109	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—sarcoma	0.000302	0.00108	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—sarcoma	0.000301	0.00108	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—sarcoma	0.000299	0.00107	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—sarcoma	0.000298	0.00107	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—sarcoma	0.000294	0.00106	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000292	0.00105	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—sarcoma	0.000292	0.00105	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—sarcoma	0.000291	0.00104	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—sarcoma	0.00029	0.00104	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—sarcoma	0.000289	0.00104	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—sarcoma	0.000289	0.00104	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—sarcoma	0.000277	0.000994	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—sarcoma	0.00027	0.000968	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—sarcoma	0.000269	0.000965	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—sarcoma	0.000268	0.000961	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—sarcoma	0.000268	0.000961	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—sarcoma	0.000263	0.000942	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—sarcoma	0.000259	0.000929	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—sarcoma	0.00025	0.000899	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—sarcoma	0.000249	0.000895	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—sarcoma	0.000243	0.000872	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—sarcoma	0.000242	0.000868	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—sarcoma	0.00024	0.00086	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—sarcoma	0.000233	0.000835	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—sarcoma	0.000232	0.000831	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—sarcoma	0.000231	0.000828	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—sarcoma	0.000231	0.000827	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—sarcoma	0.000229	0.000823	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—sarcoma	0.000224	0.000804	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—sarcoma	0.000217	0.00078	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—sarcoma	0.000215	0.000773	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—sarcoma	0.000214	0.000766	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—sarcoma	0.000213	0.000765	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—sarcoma	0.000212	0.000761	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—sarcoma	0.000201	0.000722	CcSEcCtD
